Ritonavir, ranked at position 8, is an HIV-1 protease inhibitor and CYP3A inhibitor used in combination with other antivirals to treat HIV infection and shows some ability in the inhibition of SARS-CoV-2 Mpro with IC50 of 13.7 nM (Mahdi et al. 2020). Here, CYP3A4 is linked to HIV infectious disease.